Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

News Conference News AHA 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Yael L. Maxwell

November 13, 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

News Conference News ESC 2021

SMART-MI: Implant IDs Large Burden of Arrhythmic Events Post-MI

Michael O'Riordan

August 27, 2021

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

News Daily News

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

February 27, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

News Daily News

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

June 05, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.